Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Synthetic Biology UK 2025

SynBio UK 2025 marks the 10th anniversary of the UK's leading conference in synthetic and engineering biology. Held in London, this milestone event will convene [...]

Go to Top